Sahajanand Medical Technologies' Sirolimus Eluting Stent Shows Excellent Outcomes
October 24, 2008 (PRLEAP.COM) Health NewsWASHIGTON DC Oct.24, 2008 - Sahajanand Medical Technologies Pvt. Ltd. (SMT), Surat, India, leading developer and manufacturer of Drug Eluting Stents, welcomed the positive results achieved by Supralimus Core™ (Sirolimus Eluting Stents on unique chromium cobalt platform with a biodegradable Polymer) in the MAXIMUS trial.
MAXIMUS trial was designed to assess the safety and efficacy of the Supralimus-Core™ (Sirolimus Eluting Stent) in de novo native obstructive coronary artery disease. It included 100 patients from the prestigious Max Heart Institute in India.
The study population was reflective of "real world" patients with smaller vessels, high incidence of diabetes (36%) and other cardiovascular risk factors.
The 8-months angiographic results, analyzed by Cardialysis (Rotterdam, Netherlands) showed extremely low TLR (Target Lesion Revascularization) at (1%) Stent Thrombosis (2%) at 1 year and low angiographic in-segment restenosis rates (4.6%) at 8 months. The results compare favorably to other Drug Eluting Stents current in clinically practice.
The 12 month results of MAXIMUS, which were unveiled by Dr. Ashok Seth (Chairman and Chief cardiologist, Escorts Heart Institute, New Delhi, India) on Monday, October 12th at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, DC.
"The results of Supralimus-Core in a real world population with high incidence of diabetes and relatively smaller vessels are extremely promising. It also has the additional advantage of biodegradable polymer which disappears over a period of time then alleviating some of the concern related to persistent polymer hypersensitivity." Dr. Seth commented.
Dr. Atul Abhyankar, Medical Director- Sahajanand Medical Technologies, shared the enthusiasm "The results of TLR and MACE are very low, especially the low Stent thrombosis rates at one year are very impressive and encourage us to further document these results in larger comparative trials."
Mr. Dhirajlal Kotadia, the Founder and Chairman of SMT; shared the importance of the company's commitment to continuously trying to address unmet medical needs and provide patients and clinicians with choice. We will continue our investment in clinical research and ensure the delivery of evidence-based treatments to all deserving patients around the world." he added.